CA2452044A1
(en)
|
2001-08-28 |
2003-03-13 |
Eli Lilly And Company |
Pre-mixes of glp-1 and basal insulin
|
MXPA04003569A
(es)
|
2001-10-19 |
2004-07-23 |
Lilly Co Eli |
Mezclas bifasicas de glp-1 e insulina.
|
EP1660531A2
(en)
|
2003-08-05 |
2006-05-31 |
Novo Nordisk A/S |
Novel insulin derivatives
|
AU2004269196B2
(en)
|
2003-09-03 |
2010-03-04 |
Shmuel Bukshpan |
Methods and apparatus for rapid crystallization of biomolecules
|
ATE550041T1
(de)
|
2004-01-21 |
2012-04-15 |
Novo Nordisk Healthcare Ag |
Transglutaminase-vermittelte konjugation von peptiden
|
WO2006008238A1
(en)
*
|
2004-07-16 |
2006-01-26 |
Novo Nordisk A/S |
Method for selective acylation
|
JP5080259B2
(ja)
*
|
2004-10-05 |
2012-11-21 |
ノヴォ ノルディスク アー/エス |
結晶性インスリンおよび溶解インスリンを含む薬学的調合物
|
DK1969004T3
(da)
|
2005-12-28 |
2011-11-28 |
Novo Nordisk As |
Insulinsammensætninger og metode til at lave en sammensætning
|
US8343914B2
(en)
|
2006-01-06 |
2013-01-01 |
Case Western Reserve University |
Fibrillation resistant proteins
|
EP2049149B1
(en)
*
|
2006-07-31 |
2015-04-15 |
Novo Nordisk A/S |
Pegylated extended insulins
|
PT2074141T
(pt)
|
2006-09-22 |
2016-11-10 |
Novo Nordisk As |
Análogos de insulina resistentes a proteases
|
EP2074140B8
(en)
|
2006-10-04 |
2015-10-28 |
Case Western Reserve University |
Fibrillation-resistant insulin and insulin analogues
|
US9387176B2
(en)
|
2007-04-30 |
2016-07-12 |
Novo Nordisk A/S |
Method for drying a protein composition, a dried protein composition and a pharmaceutical composition comprising the dried protein
|
US9034818B2
(en)
|
2007-06-13 |
2015-05-19 |
Novo Nordisk A/S |
Pharmaceutical formulations comprising an insulin derivative
|
KR20100053561A
(ko)
*
|
2007-08-15 |
2010-05-20 |
노보 노르디스크 에이/에스 |
아실 및 알킬렌 글리콜 부분을 갖는 인슐린 유사체
|
CA2711749A1
(en)
*
|
2008-01-09 |
2009-07-16 |
Sanofi-Aventis Deutschland Gmbh |
Novel insulin derivatives having an extremely delayed time-action profile
|
NZ586589A
(en)
|
2008-01-09 |
2012-04-27 |
Sanofi Aventis Deutschland |
Novel insulin analogues having an extremely delayed time-action profile
|
WO2009099763A1
(en)
|
2008-01-30 |
2009-08-13 |
Indiana University Research And Technology Corporation |
Ester-based peptide prodrugs
|
US9260502B2
(en)
|
2008-03-14 |
2016-02-16 |
Novo Nordisk A/S |
Protease-stabilized insulin analogues
|
PL2254906T3
(pl)
|
2008-03-18 |
2017-04-28 |
Novo Nordisk A/S |
Stabilizowane względem proteaz, acylowane analogi insuliny
|
US8993516B2
(en)
*
|
2008-04-14 |
2015-03-31 |
Case Western Reserve University |
Meal-time insulin analogues of enhanced stability
|
NZ588857A
(en)
*
|
2008-04-22 |
2012-07-27 |
Univ Case Western Reserve |
Isoform-specific insulin analogue for control blood sugar levels
|
TWI451876B
(zh)
*
|
2008-06-13 |
2014-09-11 |
Lilly Co Eli |
聚乙二醇化之離脯胰島素化合物
|
US9200053B2
(en)
|
2008-07-31 |
2015-12-01 |
Case Western Reserve University |
Insulin analogues containing penta-fluoro-Phenylalanine at position B24
|
KR20120129875A
(ko)
|
2008-07-31 |
2012-11-28 |
케이스 웨스턴 리저브 유니버시티 |
염소화 아미노산을 갖는 인슐린 유사체
|
ES2552636T3
(es)
*
|
2008-07-31 |
2015-12-01 |
Case Western Reserve University |
Insulina estabilizada por halógenos
|
AU2013237740B2
(en)
*
|
2008-07-31 |
2016-06-02 |
Case Western Reserve University |
Insulin analogues containing penta-fluora-phenyalanine at position B24
|
LT2349324T
(lt)
|
2008-10-17 |
2017-12-27 |
Sanofi-Aventis Deutschland Gmbh |
Insulino ir glp-1 agonisto derinys
|
CA2738615A1
(en)
|
2008-10-30 |
2010-05-06 |
Novo Nordisk A/S |
Treating diabetes melitus using insulin injections with less than daily injection frequency
|
MY160219A
(en)
|
2008-12-15 |
2017-02-28 |
Zealand Pharma As |
Glucagon analogues
|
WO2010070252A1
(en)
|
2008-12-15 |
2010-06-24 |
Zealand Pharma A/S |
Glucagon analogues
|
WO2010070255A1
(en)
|
2008-12-15 |
2010-06-24 |
Zealand Pharma A/S |
Glucagon analogues
|
JP5635531B2
(ja)
|
2008-12-15 |
2014-12-03 |
ジーランド ファーマ アクティーゼルスカブ |
グルカゴン類似体
|
CN102245624B
(zh)
*
|
2008-12-19 |
2016-08-10 |
印第安纳大学研究及科技有限公司 |
基于酰胺的胰岛素前药
|
EP2376098A4
(en)
*
|
2008-12-19 |
2014-06-11 |
Univ Indiana Res & Tech Corp |
DIPEPTIDE-LINKED MEDICAL AGENTS
|
AR074811A1
(es)
|
2008-12-19 |
2011-02-16 |
Univ Indiana Res & Tech Corp |
Profarmaco de peptido de la superfamilia de glucagon basados en amida
|
CN102256992B
(zh)
|
2008-12-19 |
2015-04-22 |
印第安纳大学研究及科技有限公司 |
胰岛素类似物
|
AU2009335713A1
(en)
*
|
2008-12-19 |
2010-07-15 |
Indiana University Research And Technology Corporation |
YL-based insulin-like growth factors exhibiting high activity at the insulin receptor
|
EA022816B1
(ru)
|
2009-07-13 |
2016-03-31 |
Зилэнд Фарма А/С |
Ацилированные аналоги глюкагона
|
EP2464655B1
(en)
*
|
2009-08-11 |
2017-02-15 |
Biocon Limited |
Chromatographic processes
|
US8399407B2
(en)
|
2009-09-17 |
2013-03-19 |
Case Western Reserve University |
Non-standard insulin analogues
|
JP5119232B2
(ja)
*
|
2009-11-06 |
2013-01-16 |
株式会社マルハニチロ食品 |
プロタミンの定量法
|
ES2534191T3
(es)
|
2009-11-13 |
2015-04-20 |
Sanofi-Aventis Deutschland Gmbh |
Composición farmacéutica que comprende un agonista de GLP-1, una insulina y metionina
|
PL2498801T3
(pl)
|
2009-11-13 |
2018-08-31 |
Sanofi Aventis Deutschland |
Kompozycja farmaceutyczna zawierająca desPro<sup>36</sup>eksendyno-4(1-39)-Lys6-NH2 i metioninę
|
BR112012014025A2
(pt)
*
|
2009-12-11 |
2017-01-31 |
Univ Case Western Reserve |
análogo de insulina, ácido nucleico, vetor de expressão, célula hospedeira e método de tratar um paciente
|
AR081066A1
(es)
*
|
2010-04-02 |
2012-06-06 |
Hanmi Holdings Co Ltd |
Conjugado de insulina donde se usa un fragmento de inmunoglobulina
|
US8940860B2
(en)
|
2010-06-16 |
2015-01-27 |
Indiana University Research And Technology Corporation |
Single-chain insulin agonists exhibiting high activity at the insulin receptor
|
AR081975A1
(es)
|
2010-06-23 |
2012-10-31 |
Zealand Pharma As |
Analogos de glucagon
|
EP2585482B1
(en)
|
2010-06-24 |
2019-03-27 |
Zealand Pharma A/S |
Glucagon analogues
|
KR20130102470A
(ko)
|
2010-06-24 |
2013-09-17 |
인디애나 유니버시티 리서치 앤드 테크놀로지 코퍼레이션 |
아미드계 글루카곤 슈퍼패밀리 펩티드 프로드러그
|
EP2585102B1
(en)
*
|
2010-06-24 |
2015-05-06 |
Indiana University Research and Technology Corporation |
Amide-based insulin prodrugs
|
HUE031181T2
(en)
|
2010-08-30 |
2017-06-28 |
Sanofi Aventis Deutschland |
Use of AVE0010 for the manufacture of a medicament for the treatment of type 2 diabetes
|
BR112013010345A2
(pt)
|
2010-10-27 |
2017-07-25 |
Novo Nordisk As |
tratamento de diabetes melitus usando as injeções de insulina administradas com intervalos de variação da injeção
|
EP2665487A1
(en)
|
2011-01-20 |
2013-11-27 |
Zealand Pharma A/S |
Combination of acylated glucagon analogues with insulin analogues
|
WO2012123519A2
(en)
*
|
2011-03-15 |
2012-09-20 |
Novo Nordisk A/S |
Human insulin analogues and derivatives comprising cysteine substitutions
|
US9821032B2
(en)
|
2011-05-13 |
2017-11-21 |
Sanofi-Aventis Deutschland Gmbh |
Pharmaceutical combination for improving glycemic control as add-on therapy to basal insulin
|
RU2578460C2
(ru)
|
2011-08-10 |
2016-03-27 |
Адосиа |
Приемлемый для инъекций раствор по меньшей мере одного базального инсулина
|
CN108079281A
(zh)
|
2011-08-29 |
2018-05-29 |
赛诺菲-安万特德国有限公司 |
用于2型糖尿病患者中的血糖控制的药物组合
|
AR087744A1
(es)
|
2011-09-01 |
2014-04-16 |
Sanofi Aventis Deutschland |
Composicion farmaceutica para uso en el tratamiento de una enfermedad neurodegenerativa
|
US9573987B2
(en)
|
2011-12-20 |
2017-02-21 |
Indiana University Research And Technology Corporation |
CTP-based insulin analogs for treatment of diabetes
|
EP2814461B1
(fr)
|
2012-01-09 |
2019-07-24 |
Adocia |
Solution injectable a ph 7 comprenant au moins une insuline basale dont le pi est compris entre 5,8 et 8,5 et un co-polyaminoacide substitue
|
JP2015507916A
(ja)
*
|
2012-01-20 |
2015-03-16 |
ケース ウェスタン リザーブ ユニバーシティCase Westernreserve University |
グルタミン酸安定化インスリン類似体
|
MX2014012096A
(es)
|
2012-04-11 |
2014-11-21 |
Novo Nordisk As |
Formulaciones de insulina.
|
EA028665B1
(ru)
|
2012-05-03 |
2017-12-29 |
Зилэнд Фарма А/С |
Соединения - двойные агонисты gip-glp-1 и способы
|
AR091866A1
(es)
|
2012-07-23 |
2015-03-04 |
Zealand Pharma As |
Analogos del glucagon
|
US20150314003A2
(en)
|
2012-08-09 |
2015-11-05 |
Adocia |
Injectable solution at ph 7 comprising at least one basal insulin the isoelectric point of which is between 5.8 and 8.5 and a hydrophobized anionic polymer
|
FR3001896B1
(fr)
|
2013-02-12 |
2015-07-03 |
Adocia |
Solution injectable a ph 7 comprenant au moins une insuline basale dont le point isolectrique est compris entre 5,8 et 8,5 et un polymere anionique hydrophobise
|
TWI608013B
(zh)
|
2012-09-17 |
2017-12-11 |
西蘭製藥公司 |
升糖素類似物
|
AU2013323669B2
(en)
|
2012-09-26 |
2018-03-01 |
Indiana University Research And Technology Corporation |
Insulin analog dimers
|
FR3001895B1
(fr)
|
2013-02-12 |
2015-07-03 |
Adocia |
Solution injectable a ph7 comprenant au moins une insuline basale dont le point isoelectrique est compris en 5,8 et 8,5 et un compose anionique porteur de charges carboxylates et de radicaux hydrophobes
|
TWI780236B
(zh)
|
2013-02-04 |
2022-10-11 |
法商賽諾菲公司 |
胰島素類似物及/或胰島素衍生物之穩定化醫藥調配物
|
AU2014241743B2
(en)
|
2013-03-14 |
2018-07-05 |
Indiana University Research And Technology Corporation |
Insulin-incretin conjugates
|
US10137172B2
(en)
|
2013-04-30 |
2018-11-27 |
Novo Nordisk A/S |
Administration regime
|
CA2926701A1
(en)
|
2013-10-07 |
2015-04-16 |
Novo Nordisk A/S |
Novel derivative of an insulin analogue
|
US9988429B2
(en)
|
2013-10-17 |
2018-06-05 |
Zealand Pharma A/S |
Glucagon analogues
|
ES2688708T3
(es)
|
2013-10-17 |
2018-11-06 |
Zealand Pharma A/S |
Análogos de glucagón acilados
|
MX2016005556A
(es)
|
2013-11-06 |
2016-07-15 |
Zealand Pharma As |
Compuestos agonistas duales de gip-glp-1 y procedimientos.
|
CN105829339B
(zh)
|
2013-11-06 |
2021-03-12 |
西兰制药公司 |
胰高血糖素-glp-1-gip三重激动剂化合物
|
FR3013049B1
(fr)
*
|
2013-11-14 |
2015-11-13 |
You-Ping Chan |
Analogue de l'insuline glargine
|
SG11201604708VA
(en)
|
2014-01-09 |
2016-07-28 |
Sanofi Sa |
Stabilized glycerol free pharmaceutical formulations of insulin analogues and/or insulin derivatives
|
KR20160104724A
(ko)
|
2014-01-09 |
2016-09-05 |
사노피 |
인슐린 유사체 및/또는 인슐린 유도체의 안정화된 약제학적 제형
|
CN114939156A
(zh)
|
2014-01-09 |
2022-08-26 |
赛诺菲 |
门冬胰岛素的稳定化药物制剂
|
AR099569A1
(es)
|
2014-02-28 |
2016-08-03 |
Novo Nordisk As |
Derivados de insulina y los usos médicos de estos
|
US9656017B2
(en)
|
2014-06-20 |
2017-05-23 |
Howard E. Greene |
Infusion delivery devices and methods
|
US10385107B2
(en)
|
2014-09-24 |
2019-08-20 |
Indiana Univeresity Researc and Technology Corporation |
Lipidated amide-based insulin prodrugs
|
US10232020B2
(en)
|
2014-09-24 |
2019-03-19 |
Indiana University Research And Technology Corporation |
Incretin-insulin conjugates
|
JP6829928B2
(ja)
|
2014-10-06 |
2021-02-17 |
ケース ウェスタン リザーブ ユニバーシティCase Western Reserve University |
二相性単鎖インスリン類似体
|
JP6898231B6
(ja)
|
2014-10-29 |
2021-07-28 |
ジーランド ファーマ アクティーゼルスカブ |
Gipアゴニスト化合物及び方法
|
US9950039B2
(en)
|
2014-12-12 |
2018-04-24 |
Sanofi-Aventis Deutschland Gmbh |
Insulin glargine/lixisenatide fixed ratio formulation
|
TWI748945B
(zh)
|
2015-03-13 |
2021-12-11 |
德商賽諾菲阿凡提斯德意志有限公司 |
第2型糖尿病病患治療
|
TW201705975A
(zh)
|
2015-03-18 |
2017-02-16 |
賽諾菲阿凡提斯德意志有限公司 |
第2型糖尿病病患之治療
|
AU2016247499B2
(en)
|
2015-04-16 |
2020-09-03 |
Zealand Pharma A/S |
Acylated glucagon analogue
|
AR105616A1
(es)
|
2015-05-07 |
2017-10-25 |
Lilly Co Eli |
Proteínas de fusión
|
FR3052072A1
(fr)
|
2016-06-07 |
2017-12-08 |
Adocia |
Solution injectable a ph 7 comprenant au moins une insuline basale dont le pi est compris entre 5,8 et 8,5 et un co-polyaminoacide porteur de charges carboxylates et de radicaux hydrophobes
|
EP3554534B1
(en)
|
2016-12-16 |
2021-06-23 |
Novo Nordisk A/S |
Insulin containing pharmaceutical compositions
|
KR20180002062U
(ko)
|
2016-12-28 |
2018-07-06 |
유애자 |
크리스탈이 구비된 조명커버
|
FR3070264A1
(fr)
|
2017-08-24 |
2019-03-01 |
Adocia |
Solution injectable a ph 7 comprenant au moins une insuline basale dont le pi est compris de 5,8 a 8,5 et un co-polyaminoacide porteur de charges carboxylates et de radicaux hydrophobes
|
FR3083089A1
(fr)
|
2018-06-29 |
2020-01-03 |
Adocia |
Solution injectable a ph 7 comprenant au moins une insuline basale dont le pi est compris entre 5,8 et 8,5 et un co-polyaminoacide porteur de charges carboxylates et de radicaux hydrophobes
|
FR3083088B1
(fr)
|
2018-06-29 |
2020-10-02 |
Adocia |
Solution injectable a ph 7 comprenant au moins une insuline basale dont le pi est compris entre 5,8 et 8,5 et un co-polyaminoacide porteur de charges carboxylates et de radicaux hydrophobes
|
EP3720472A1
(fr)
|
2017-12-06 |
2020-10-14 |
Adocia |
Solution injectable a ph 7 comprenant au moins une insuline basale dont le pi est compris entre 5,8 et 8,5 et un co-polyaminoacide porteur de charges carboxylates et de radicaux hydrophobes
|
MA51127A
(fr)
|
2017-12-07 |
2021-03-17 |
Adocia |
Solution injectable a ph 7 comprenant au moins une insuline basale dont le pi est compris entre 5,8 et 8,5 et un co-polyaminoacide porteur de charges carboxylates et de radicaux hydrophobes
|
WO2019110773A1
(fr)
|
2017-12-07 |
2019-06-13 |
Adocia |
Solution injectable a ph 7 comprenant au moins une insuline basale dont le pi est compris entre 5,8 et 8,5 et un co-polyaminoacide porteur de charges carboxylates et de radicaux hydrophobes
|
WO2019243628A1
(fr)
|
2018-06-22 |
2019-12-26 |
Adocia |
Composition injectable a ph 7 comprenant un co-polyaminoacide porteur de charges carboxylates et de radicaux hydrophobes et au moins une insuline basale presentant au moins un effet prandial et un effet basal
|
US10335464B1
(en)
|
2018-06-26 |
2019-07-02 |
Novo Nordisk A/S |
Device for titrating basal insulin
|
FR3084585B1
(fr)
|
2018-08-03 |
2020-11-06 |
Adocia |
Solution injectable a ph 7 comprenant au moins une insuline basale dont le pi est compris entre 5,8 et 8,5 et un compose amphiphile porteur de radicaux hydrophobes
|
US20200179489A1
(en)
|
2018-12-07 |
2020-06-11 |
Adocia |
Injectable solution at ph 7 comprising at least one basal insulin which pi is from 5.8 to 8.5 and a co-polyamino-acid bearing carboxylate charges and hydrophobic radicals and a limited amount of m-cresol
|
WO2020115334A1
(fr)
|
2018-12-07 |
2020-06-11 |
Adocia |
Procede de preparation d'une composition stable sous forme d'une solution aqueuse injectable
|
WO2020245470A1
(fr)
|
2019-06-07 |
2020-12-10 |
Adocia |
Solution injectable a ph 7 comprenant au moins une insuline basale dont le pi est compris entre 5,8 et 8,5, du liraglutide et un co-polyaminoacide porteur de charges carboxylates et de radicaux hydrophobes
|